Platinum-containing compounds, methods for their preparation and applications thereof

• US 5,714,327 A
• Filed: 06/06/1995
• Issued: 02/03/1998
• Est. Priority Date: 07/19/1990
• Status: Expired due to Term

• Current Assignee: Kreatech Diagnostics (Danaher Corporation)
• Original Assignee: Kreatech Diagnostics (Danaher Corporation)
• Inventors: Van Es, Remco Maria, Lempers, Edwin Leo Marlo, Jelsma, Tinka, Reedijk, Jan, Bloemink, Marieke Johanna, van den Berg, Franciscus Michiel, Houthoff, Hendrik J.
• Primary Examiner(s): Guzo, David
• Assistant Examiner(s): SANDALS, WILLIAM O
• Application Number:
  US08/470,265
• Time in Patent Office: 973 Days
• Field of Search: 435/975, 435/6, 435/7.1, 435/7.5, 436/84, 436/501, 436/800, 436/513, 536/23.1, 536/24.3, 556/136, 424/64.9
• US Class Current: 435/6.11
• CPC Class Codes: C07F 15/0093 without a metal-carbon linkage
• CPC Class Codes: C07J 51/00 Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
• CPC Class Codes: C09B 11/04 derived from triarylmethanes , i.e. central C-atom is substituted by amino, cyano, alkyl
• CPC Class Codes: C12Q 1/6816 characterised by the detection means C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 2563/137 Metal/ion, e.g. metal label

Abstract

The invention provides platinum-based probe compounds having the structure: ##STR1## wherein: Pt is a platinum atom, PROBE is a probe biomolecule for associating to a target biomolecule, M is a detectable marker moiety, and X and Y are stabilizing substituents. Also provided are platinum-based labeling compounds having the structure: ##STR2## wherein: Pt is a platinum atom, M is a detectable marker moiety, A is a displaceable leaving group, and X and Y are stabilizing substituents. The invention further provides platinum-based linker compounds having the structure: ##STR3## wherein: Pt is a platinum atom, A and B are the same or different reactive moieties, and X and Y are stabilizing substituents. Other Pt^II and Pt^IV compounds are also provided. Moreover, the invention provides methods for the preparation and use of these compounds, as well as diagnostic kits which contain the compounds.

Claims

1. A detectable probe compound, having the structure:

##STR35## wherein;

Pt is a platinum atom;

PROBE is a probe biomolecule;

M is a detectable marker moiety; and

X and Y are stabilizing substituents.

2. The detectable probe compound of claim 1, wherein PROBE comprises a biomolecule selected from the group consisting of nucleic acids, proteins, and lipids.

3. The detectable probe compound of claim 1, wherein PROBE comprises a biomolecule selected from the group consisting of nucleotides, nucleosides, modified nucleotides, modified nucleosides, oligonucleotides, polynucleotides, amino acids, modified amino acids, oligopeptides, polypeptides, proteins, glycoproteins, lipoproteins, steroids, and fatty acids.

4. The detectable probe compound of claim 1, wherein X and Y are interconnected forming a stabilizing bridge moiety.

5. A diagnostic kit for detecting a target biomolecule, comprising a container housing a detectable probe compound as defined in claim 1.

6. The detectable probe compound of claim 1, wherein M comprises a detectable marker moiety selected from the group consisting of radioactive labels, enzymes, specific binding pair components, colloidal dye substances, fluorochromes, chromogens, reducing substances, colored latex sols, metal sols, particulate sols, dansyl lysine, antibodies, protein A, and protein G.

7. The detectable probe compound of claim 6, wherein M comprises a fluorochrome selected from the group consisting of fluoresceins, eosins, trisulfonylpyrenes, rhodamines, digoxigenins, and 4,4-difluoro-4-bora-3a,4a-diaza-s-indacenes.

8. The detectable probe compound of claim 6, wherein M comprises a specific binding pair component selected from the group consisting of biotins, iminobiotins, avidins, streptavidins, and biocytins.

9. The detectable probe compound of claim 4, wherein the stabilizing bridge moiety comprises an aliphatic diamine having 2-6 carbon atoms.

10. The detectable probe compound of claim 9, wherein the aliphatic diamine comprises ethylenediamine.

11. A method for detecting a biological target molecule, comprising:

(a) providing to a testable system a platinum-based detectably labeled probe having the structure;

##STR36## wherein;

Pt is a platinum atom,

PROBE is a probe biomolecule for associating to a biological target molecule,

M is a detectable marker moiety, and

X and Y are stabilizing substituents; and

(b) measuring an amount of association between said detectably labeled probe and said target biomolecule.

12. The method of claim 11, wherein said PROBE associates selectively to said biological target molecule.

13. The method of claim 11, wherein said PROBE associates specifically to said biological target molecule.

14. The method of claim 11, wherein said PROBE comprises a nucleic acid molecule selected from the group consisting of natural, modified, synthetic, and recombinant nucleotides, oligonucleotides, DNA, RNA, homoduplexes, heteroduplexes, and multiplexes.

15. The method of claim 11, wherein said providing step comprises in situ hybridizing said detectable probe compound with a specific nucleic acid target sequence.

16. The method of claim 11, wherein said PROBE and said biological target molecule comprise complementary members of a specific binding pair.

17. The method of claim 16, wherein said specific binding pair is selected from the group consisting of antibody-antigen, antibody-hapten, complementary nucleic acids, avidin-biotin, streptavidin-biotin, protein subunit-protein subunit, enzyme-substrate, enzyme-enzyme, enzyme-cofactor, enzyme-inhibitor, receptor-agonist, receptor-antagonist, saccharide-lectin, glycoprotein-lectin, and glycolipid-lectin.

18. The method of claim 11, wherein M comprises a detectable marker moiety selected from the group consisting of radioactive labels, enzymes, specific binding pair components, colloidal dye substances, fluorochromes, chromogens, reducing substances, colored latex sols, metal sols, particulate sols, dansyl lysine, antibodies, protein A, and protein G.

19. The method of claim 18, wherein M comprises a fluorochrome selected from the group consisting of fluoresceins, eosins, trisulfonylpyrenes, rhodamines, digoxigenins, and 4,4-difluoro-4-bora-3a,4a-diaza-s-indacenes.

20. The method of claim 18, wherein M comprises a specific binding pair component selected from the group consisting of biotins, iminobiotins, avidins, streptavidins, and biocytins.

21. A method of detectably labeling a biomolecule, comprising:

reacting a detectable label compound having the structure;

##STR37## wherein;

Pt is a platinum atom;

M is a detectable marker moiety;

A is a displaceable leaving group; and

X and Y are stabilizing substituents,

with a biomolecule which is to be detectably labeled.